The Antaki Synthesis

Three-component condensation for hexahydroquinoline formation — first reported by H. Antaki, Research Institute for Tropical Medicine, Cairo, 1963

The Synthesis

In 1963, Hekmat Bechir Fathallah Antaki reported the first synthesis of ethyl 4-aryl-1,4,5,6,7,8-hexahydro-2-methyl-5-oxoquinoline-3-carboxylates via three-component condensation of cyclohexane-1,3-dione, aromatic aldehydes, and ethyl β-aminocrotonate in ethanol and glacial acetic acid under reflux for one hour.

The synthesis requires no transition metal catalysts, no inert atmosphere, and no specialised equipment. The three starting materials are commercially available and inexpensive. The product crystallises directly from the reaction mixture. Antaki reported a full series of aryl substituents at the 4-position — p-nitrophenyl, p-methoxyphenyl, 3,4-dimethoxyphenyl, p-dimethylaminophenyl, p-chlorophenyl, and o-nitrophenyl derivatives — with melting points and elemental analyses fully documented.

The hexahydroquinoline intermediates were further subjected to oxidative dehydrogenation by chromium trioxide in dilute acetic acid to yield the corresponding 5,6,7,8-tetrahydroquinolines, demonstrating controlled manipulation of scaffold oxidation state.

Original Reaction Conditions (1963)

Parameter	Detail
Reactants	Cyclohexane-1,3-dione · Aromatic aldehyde · Ethyl β-aminocrotonate
Solvent	Ethanol and glacial acetic acid
Temperature	Reflux
Reaction time	1 hour
Workup	Product crystallises directly from the reaction mixture
Catalyst	None — no transition metal catalysts required
Atmosphere	Ambient — no inert atmosphere required
Aryl substituents reported	p-nitrophenyl, p-methoxyphenyl, 3,4-dimethoxyphenyl, p-dimethylaminophenyl, p-chlorophenyl, o-nitrophenyl
Oxidation step	Chromium trioxide in dilute acetic acid — converts hexahydroquinolines to tetrahydroquinolines

The significance of the 1963 paper extends beyond the synthesis of specific compounds. By systematically varying the aryl substituent at the 4-position across six electronically distinct groups, Antaki established the 4-aryl position as a modifiable site whose electronic character directly influences the scaffold's properties. The hexahydroquinoline framework is now recognised as a privileged scaffold in medicinal chemistry: a molecular platform that accommodates systematic structural variation at key positions to yield compounds active across multiple therapeutic targets. The six variants documented in 1963 were not an inventory of products. They were the first demonstration that this position could be tuned — the foundational evidence that the scaffold was a tool, not merely a molecule.

This synthesis has been formally classified as the Antaki synthesis — alongside the Hantzsch and Stankevich reactions — as one of three foundational multicomponent methods for hexahydroquinoline formation:

"These approaches established the mechanistic foundation for multicomponent HHQ formation and provided a framework for structural diversification in modern synthesis." — Oduselu et al., Frontiers in Chemistry, 2026

The Chemistry of Heterocyclic Compounds, the 1963 and 1965 papers in Acheson's Vol. 9 (1973), the standard reference for the cyclohexane-1,3-dione / ammonium acetate condensation; the 1963 paper again in Thummel's "Carbocyclic Annelated Pyridines" (Part 5, 1984). Comprehensive Heterocyclic Chemistry (Pergamon) — G. Jones cites the 1963 paper as the sole reference for the cyclohexane-1,3-dione variant of the Hantzsch synthesis (1st ed., 1984).

The 1963 paper is cited as reference 324 in Acheson, R.M. (ed.), Chemistry of Heterocyclic Compounds, Vol. 9 (Wiley, 1973) — the canonical Wiley heterocyclic chemistry reference series.

Bossert & Vater — Medicinal Research Reviews, 1989 DOI: 10.1002/med.2610090304

"hexahydroquinoline derivatives aroused our interest."

Friedrich Bossert and Wulf Vater, inventors of nifedipine. Reference 7 in that paper is Antaki, J. Chem. Soc., 1963. He appears again as reference 13, when the authors place his work in the historical synthetic lineage alongside the classic Hantzsch and Knoevenagel reactions. This review has been cited thousands of times.

Pharmaceutical Confirmation

Independent patent families citing Antaki's 1963 synthesis as prior art include filings by ICI/AstraZeneca (1991), Gilead Sciences (2014), and Shin Nippon Biomedical Laboratories (2013), spanning cardiovascular, urological, and transporter pharmacology across more than two decades.

Antimalarial Relevance

The hexahydroquinoline scaffold has attracted renewed pharmaceutical interest in antimalarial drug discovery as resistance to artemisinin-based therapies grows. Antaki directed his programme explicitly toward antiparasitic applications: "In continuation of previous work on the schistosomicidal activity in the pyrido[1,2-a]pyrimidine series, the synthesis of some basic derivatives was considered." — H. Antaki, J. Org. Chem., 1962 He was working on diseases of the poor, with tools accessible to resource-limited laboratories, six decades before the current antimalarial interest in this scaffold.

Primary Source

Antaki, H. The Synthesis of Ethyl 4-Aryl-5,6,7,8-tetrahydro-5-oxoquinoline-3-carboxylates and their Derivatives. J. Chem. Soc. 1963, 4877–4879. DOI: 10.1039/jr9630004877

hekmatantaki.org